Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar;30(3):478–489. doi: 10.3201/eid3003.230893

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.

PMC Copyright notice

Vaccine effectiveness against death among persons >65 years of age in a population-based evaluation of vaccine effectiveness against SARS-CoV-2 infection, severe illness, and death, Taiwan, March 22, 2021–September 30, 2022. The study investigated various vaccine types: mRNA (Pfizer-BioNTech BNT162b2 [https://www.pfizer.com] and Moderna mRNA-1273 [https://www.modernatx.com]), protein subunit (Medigen MVC-COV1901 [https://www.medigenvac.com]), and viral vector–based vaccines (Oxford-AstraZeneca AZD1222 [https://www.astrazeneca.com]). The forest plot demonstrates effectiveness of different vaccination regimens status against death for persons >65 years of age. Blue diamonds indicate percentage effectiveness; bars indicate 95% CIs. AZ, AstraZeneca vaccine.